Durolane Unpacking HA

Not all Hyaluronic Acids are the same….
DUROLANE has the highest reported molecular weight of any HA – 1015kDa

DUROLANE is a non-animal, stabilized HA that is cross-linked and entangled to create an HA with a long residence time.

High molecular weight (HMW) HAs are superior to low molecular weight (LMW) HAs and other nonsurgical therapies for the management of osteoarthritis (OA)

“Amalgamation of LMW and HMW may have 35 blurred the benefits 30 of intraarticular HA 25 (IAHA) in the past, 20 leading to negative 15 recommendations.”

  • Meta-analyses have demonstrated that HMW HAs (≥ 3,000 kDa) are superior to LMW (< 3,000 kDA) HAs on both pain and function outcomes.
  • HMW HAs are the only HA formulation to consistently exceed the minimum clinically important improvement (MCII) threshold set by clinical practice guidelines such as the AAOS recommendations on osteoarthritis management

Not all Hyaluronic Acids are the same

the durolane® difference

Product Source Modification Process Cross-linking Agent Average Molecular Weight (kDA) Half-life Injection Regimen Concentration
DUROLANE1 Bacterial Fermentation Mild Stabilisation <1% BDDE Linker* >100 billion 3D gel particles 28 Days 1 60 mg/3 mL
Synvisc-One62
(hylan G-F 20)		 Rooster Combs Highly Cross-linked; 20% Formaldehyde and Divinyl Sulfone 6000 + Gel 8-10 Days 1 48 mg/6 mL
Monovisc63 Bacterial Fermentation Lightly Cross-linked Proprietary Cross-linker 1950 Unknown 1 88 mg/4 mL
(Nominal Amount)
Synvisc64
(hylan G-F 20)		 Rooster Combs Highly Cross-linked; 20% Formaldehyde and Divinyl Sulfone 6000 + Gel 8-10 Days 3 16 mg/2 mL
Euflexxa65 Bacterial Fermentation Nil Nil 3000 Unknown 3 20 mg/2 mL
Orthovisc66 Bacterial Fermentation Nil Nil 1950 Unknown 3 30 mg/2 mL

PROVEN CLINICAL AND COST-EFFECTIVENESS

  • The typical follow-up period of RCT
    studies evaluating intraarticular injectables
    for OA is 3-6 months
  • Most patients live with OA for
    many years prior to total joint
    replacement
  • In a 6-year cohort study with 623 patients, pain
    relief from DUROLANE injections was sustained
    for an average 466.8 days (15.3 months) post
    initial treatment
  • Repeat IAHA injections are
    associated with delay to time
    to total joint replacement

Choose DUROLANE for:

  • Reductions in opioid and analgesic use
  • Improved quality of life and overall cost effectiveness vs standard of care
  • Reduced adverse outcome-related costs

2. Half-Life of 30 days

3. Joint Residence Time of 150 days

  • Total joint residence time of approx 150 days based on half-life of 30 days
  • Half life of 30 days (approximately 4 weeks) in the knee joint in a single injection treatment regimen
  • The longest reported joint residence time of any HA

4. Powerful and Lasting Pain Relief

  • No risk of adverse reaction (NO Rooster Derivatives)
  • Long lasting up to 15 months
  • More powerful lasting pain relief versus MPA*
  • More powerful pain relief versus Synvisc-One
  • Unique formulation in a single injection treatment
  • Uses NASHA® technology to:
    • Increase residence time in the joint
    • Impart unique viscoelastic properties compared to other hyaluronic acid (HA)

5. Numbers that speak for themselves